https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/03/aac-serv-spec-jan-2016.pdf<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-02-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-27T14:00:16.997Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Motor Neurone Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking to support people living with motor neurone disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "14853"}
, {"_about" : "http://data.parliament.uk/resources/1687356", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1687356/answer", "answerText" : {"_value" : "NHS England is committed to delivering high quality care and support for every person with dementia at every age, and central to this is the provision of personalised care. Provision of dementia health care services is the responsibility of local integrated care boards (ICBs). NHS England would expect ICBs to commission services based on local population needs.<\/p>
<\/p>
The Dementia Well Pathway includes diagnosing well, living well, supporting well, and dying well, and highlights that services need to be integrated, commissioned, monitored, and aligned with the National Institute for Health and Care Excellence\u2019s (NICE) standards for each component of the pathway. It makes it clear that individual needs, wishes and preferences should be taken into account in planning and providing care.<\/p>
<\/p>
In January 2023 the Government announced that it will publish a Major Conditions Strategy early 2024. By bringing dementia and other conditions strategies together, we will be able to focus on where there are similarities in approach and ensure care is better centred around the patient.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4527", "label" : {"_value" : "Biography information for Helen Whately"}
}
, "answeringMemberConstituency" : {"_value" : "Faversham and Mid Kent"}
, "answeringMemberPrinted" : {"_value" : "Helen Whately"}
, "dateOfAnswer" : {"_value" : "2024-02-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-27T14:20:12.213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dementia: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help support people with early onset dementia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "12951"}
, {"_about" : "http://data.parliament.uk/resources/1687357", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1687357/answer", "answerText" : {"_value" : "
From July 2022, under the Health and Care Act 2022, Care Quality Commission registered health and care providers are required to ensure that staff receive training on learning disability and autism appropriate to their role. This will help to ensure that staff have the right knowledge and skills to provide safe and compassionate care for people with a learning disability.<\/p>
We are taking steps to help care homes improve the support they provide through the Care Workforce Pathway that sets clear expectations about training at different stages of a career. This includes learning disability and dementia as specific areas of practice. We are also introducing a new Level 2 Adult Social Care Certificate available to the sector with content that has been underpinned by the Dementia Training Standards and the Core Capabilities Framework on learning disability.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4527", "label" : {"_value" : "Biography information for Helen Whately"}
}
, "answeringMemberConstituency" : {"_value" : "Faversham and Mid Kent"}
, "answeringMemberPrinted" : {"_value" : "Helen Whately"}
, "dateOfAnswer" : {"_value" : "2024-02-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-16T12:56:07.62Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Care Homes: Dementia and Learning Disability"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help care homes to improve the support they provide to people with (a) learning difficulties and (b) dementia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "12952"}
, {"_about" : "http://data.parliament.uk/resources/1665019", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1665019/answer", "answerText" : {"_value" : "
Patients with pulmonary fibrosis are cared for by National Health Service regional specialist Interstitial Lung Disease (ILD) services, who are commissioned by NHS England. To be referred to a specialist service patients need to be identified in primary and secondary care. Early and accurate diagnosis is a priority for NHS England, and the work to improve this area of clinical care is underway, which should have an impact on reducing delayed diagnosis of pulmonary fibrosis.<\/p>
NHS England is responsible for the commissioning of services for ILD and funds the cost of anti-fibrotic treatments to treat this disease. Access to these treatments has recently been expanded to patients with non-idiopathic pulmonary fibrosis following the publication of the National Institute for Health and Care Excellence\u2019s technology appraisal \u2018Nintedanib for treating progressive fibrosing interstitial lung diseases\u2019 in November 2021.<\/p>
The Department has no plans for an awareness campaign.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "202714"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T15:57:32.3Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Lung Diseases: Health Education"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase awareness of pulmonary fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "202713"}
, {"_about" : "http://data.parliament.uk/resources/1665020", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1665020/answer", "answerText" : {"_value" : "
Patients with pulmonary fibrosis are cared for by National Health Service regional specialist Interstitial Lung Disease (ILD) services, who are commissioned by NHS England. To be referred to a specialist service patients need to be identified in primary and secondary care. Early and accurate diagnosis is a priority for NHS England, and the work to improve this area of clinical care is underway, which should have an impact on reducing delayed diagnosis of pulmonary fibrosis.<\/p>
NHS England is responsible for the commissioning of services for ILD and funds the cost of anti-fibrotic treatments to treat this disease. Access to these treatments has recently been expanded to patients with non-idiopathic pulmonary fibrosis following the publication of the National Institute for Health and Care Excellence\u2019s technology appraisal \u2018Nintedanib for treating progressive fibrosing interstitial lung diseases\u2019 in November 2021.<\/p>
The Department has no plans for an awareness campaign.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "202713"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T15:57:32.273Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Lung Diseases: Diagnosis and Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to (a) early diagnosis and (b) treatment for people living with pulmonary fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "202714"}
, {"_about" : "http://data.parliament.uk/resources/1663068", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1663068/answer", "answerText" : {"_value" : "
To be made routinely available to National Health Service patients in England, new medicines must receive a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) and a positive recommendation from the National Institute for Health and Care Excellence (NICE) to demonstrate clinical and cost effectiveness.<\/p>
A number of potential new disease modifying treatments for Alzheimer\u2019s disease are in development and MHRA, NICE, NHS England and the Department are working closely to ensure that arrangements are in place to support the adoption of any new licensed and NICE recommended treatment for Alzheimer\u2019s disease as soon as possible.<\/p>
NICE\u2019s appraisal of lecanemab for treating early Alzheimer's disease is currently underway and, subject to licensing and the company engaging in the process, NICE expects to publish final guidance in July 2024 as close to licence as possible. NICE is also due to begin its appraisal of donanemab for treating early Alzheimer\u2019s disease later this year.<\/p>
To prepare for these appraisals, and the expected pipeline of further disease modifying dementia treatments, the NICE Health Technology Assessment Innovation Laboratory has already started working on identifying potential challenges that might face the evaluation of these medicines and ways of addressing them.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T14:38:04.853Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Dementia: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that new disease-modifying treatments for dementia will be available on the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "200922"}
, {"_about" : "http://data.parliament.uk/resources/1663630", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1663630/answer", "answerText" : {"_value" : "
The majority of health services for people with epilepsy are commissioned locally by integrated care boards (ICBs). ICBs are best placed to make decisions regarding the provision of health services to their local population, including for the treatment of epilepsy, subject to local prioritisation and funding.<\/p>
At a national level, there are several initiatives supporting service improvement for those with epilepsy, including NHS England\u2019s Neuroscience Service Transformation Programme and RightCare Epilepsy Toolkit.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T16:16:01.423Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Epilepsy: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support people living with epilepsy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "201484"}
, {"_about" : "http://data.parliament.uk/resources/1663631", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1663631/answer", "answerText" : {"_value" : "
The Department has no role in the costs of medicines purchased in the private sector.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4423", "label" : {"_value" : "Biography information for Will Quince"}
}
, "answeringMemberConstituency" : {"_value" : "Colchester"}
, "answeringMemberPrinted" : {"_value" : "Will Quince"}
, "dateOfAnswer" : {"_value" : "2023-10-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-10-19T14:42:20.233Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-10-13", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Patients"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help manage the (a) affordability and (b) value for money in the cost of medicines purchased by patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4079", "label" : {"_value" : "Biography information for Julian Sturdy"}
}
, "tablingMemberConstituency" : {"_value" : "York Outer"}
, "tablingMemberPrinted" : [{"_value" : "Julian Sturdy"}
], "uin" : "201485"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&tablingMemberPrinted.=Julian+Sturdy&tablingMember.label=Biography+information+for+Julian+Sturdy&_page=1&max-answer.questionFirstAnswered.=2024-03-20T11%3A39%3A46.747Z", "page" : 0, "startIndex" : 1, "totalResults" : 319, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}